- Vuse Pro device uses technology to unlock after verifying adult consumers are at least 21 years old and above the legal minimum purchase age to purchase tobacco and vapor products
- Vuse Pro device works with Vuse Pro pods
- Reynolds has provided the FDA with nearly 80,000 pages of scientific data for review as part of the submission, including 97 scientific studies.
Winston-Salem, N.C. (June 27, 2024)— R.J. Reynolds Vapor Company (RJRVC), an operating company of Reynolds American Inc. (Reynolds American), the BAT Group’s U.S. subsidiary, has filed its final Pre-Market Tobacco Product Application (PMTA) submissions with the U.S. Food and Drug Administration (FDA) for the Vuse Pro age-gated device. The electronic nicotine delivery system (ENDS) device platform connects to a mobile application that verifies the consumer’s age through a third-party provider prior to unlocking for use.
The BAT Group’s strategic aim is to offer adult smokers innovative, smokeless products to Build a Smokeless World. Today’s submission by RJRVC is another important milestone in the transformation, while at the same time underscoring Reynolds American’s commitment to underage access prevention. Vuse Pro uses a combination of technology and responsible innovation to verify a consumer’s age.
Once verified, the device will unlock and can be used with the exclusively compatible Vuse Pro pods. The cutting-edge technology and mobile application also enable features such as auto-lock and proximity lock to further secure device access.
“Our PMTA submissions to the FDA underscore our commitment to both offering adult tobacco and vapor consumers choices as well as underage access prevention,” said Reynolds Executive Vice President of Scientific Research and Development Tim Nestor. “We don’t want our products in the hands of youth, period. The Vuse Pro ENDS platform provides a solution that limits access to adult consumers while also offering flavors that appeal to current adult smokers and a unique vapor experience.”
Any new-to-market tobacco product must receive FDA authorization before it can be sold in the United States. Reynolds’s PMTA provided the FDA with nearly 80,000 pages of scientific evidence through 97 scientific studies.
To learn more about Reynolds and its companies, including our comprehensive scientific research and development, visit ReynoldsAmerican.com.
###
About Reynolds American Inc.: Reynolds American Inc. is a wholly owned U.S. subsidiary of the global BAT Group and the U.S. parent company of R.J. Reynolds Tobacco Company, Santa Fe Natural Tobacco Company, Inc., American Snuff Company, LLC, R.J. Reynolds Vapor Company, and Modoral Brands Inc. (the “Subsidiaries”). The Subsidiaries operate and conduct separate, distinct businesses. References to “Reynolds American,” “Reynolds,” “the group,” “the company,” “we,” “us,” and “our” are simply for convenience and are not intended to imply or suggest that the Subsidiaries’ businesses are operated other than as separate, distinct businesses.
Media Contact:
mediaoffice@rjrt.com
